BOSTON – Tapering but perhaps not completely stopping tumor necrosis factor inhibitors can result in good control of rheumatoid arthritis with considerable cost savings, according to investigators in...
BOSTON – A nonsteroidal investigational drug that acts on the glucocorticoid receptor was superior to placebo and noninferior to higher-dose prednisone in adults with rheumatoid arthritis,...
BOSTON – Golimumab was significantly better than placebo at reducing disease activity and inflammation in patients with nonradiographic axial spondyloarthritis, but only among those who were positive...
SAN FRANCISCO – Patients who did not undergo elective surgical resection after successful percutaneous drainage of a diverticular-associated abscess had low rates of recurrent diverticulitis in a...
BOSTON– In the search for safer alternatives to glucocorticoid therapy, DAGR (PF-0417327) may prove to be a contender. The investigational drug is a selective, high-affinity, dissociated agonist of...
BERLIN – The first-ever dementia risk score designed specifically for patients with type 2 diabetes has successfully undergone external validation and is ready for everyday use by clinicians, Rachel...
SAN FRANCISCO – Too much or too little IV fluid on the day of surgery was associated with a 10%-12% increased risk for postoperative ileus in a retrospective study of 84,722 patients undergoing colon...
BOSTON – It took 10 years to find out that mycophenolate mofetil and azathioprine are comparable as maintenance therapies for patients with lupus nephritis, at least in a European population.
Or as...
BOSTON – Two investigational monoclonal antibodies, each targeting a different cytokine, showed good activity against systemic lupus erythematosus in two separate studies presented at the annual...
BOSTON – Secukinumab showed enduring efficacy in ankylosing spondylitis after 52 weeks of treatment, based on data reported at the annual meeting of the American College of Rheumatology.
The...